Caring Ambassadors Program
Hepatitis C
Newsletter
www.HepCChallenge.org
February 2012
Clinical
Trials, Cohort Studies, Pilot Studies
Re-treatment of previous
non-responders and relapsers to interferon plus ribavirin with peginterferon
alfa-2a (40KD), ribavirin ± amantadine
in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG, Cheinquer H, Almeida
PR, et al. Ann Hepatol. 2012 Jan-Feb;11(1):52-61.
http://www.ncbi.nlm.nih.gov/pubmed/22166561
Predictors of Changes in
Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated
Interferon-α Hu CC, Weng CH, Lin CL, et al. Ren Fail. 2012 Jan 23. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22264026
Impact of
IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in
Chronic Hepatitis C Genotype 2 and 3. Rembeck K, Alsiö
A, Christensen PB, et al. PLoS One. 2012;7(1):e29370. Epub 2012 Jan 13.
http://www.ncbi.nlm.nih.gov/pubmed/22253715
Type 2 diabetes mellitus and
chronic hepatitis C: Which is worse? Results of a long-term retrospective
cohort study. Giordanino C, Ceretto
S, Bo S, Smedile A, et al. Dig Liver Dis. 2012 Jan 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22245505
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin
in a randomized trial of hepatitis C genotype 1 patients. Nelson
DR, Zeuzem S, Andreone P, et
al. Ann Hepatol. 2012 Jan-Feb;11(1):15-31.
http://www.ncbi.nlm.nih.gov/pubmed/22166557
Ribavirin dose and treatment outcome of Korean
patients with genotype 1 chronic hepatitis C. Sinn
DH, Kim J, Shin SR, et al. Hepatogastroenterology.
2012 Jan-Feb;59(113):1-6. doi: 10.5754/hge11387.
http://www.ncbi.nlm.nih.gov/pubmed/21940368
Optimal
follow-up time to determine the sustained virological
response in patients with chronic hepatitis C receiving pegylated-interferon
and ribavirin. Namikawa M, Kakizaki S, Yata Y, et al. J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi:
10.1111/j.1440-1746.2011.06802.x.
http://www.ncbi.nlm.nih.gov/pubmed/21649727
Predictive value of early viral
dynamics during peginterferon and ribavirin
combination therapy based on genetic polymorphisms near the IL28B gene in
patients infected with HCV genotype 1b. Toyoda H, Kumada T, Tada T, et al. J Med Virol.
2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.
http://www.ncbi.nlm.nih.gov/pubmed/22095536
Preliminary
study of two antiviral agents for hepatitis C genotype 1. Lok AS,
Gardiner DF, Lawitz E, et al. N Engl
J Med. 2012 Jan 19;366(3):216-24.
http://www.ncbi.nlm.nih.gov/pubmed/22256805
Factors linked to severe
thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and
pretreatment low platelet counts. Lin KH, Hsu PI, Yu HC, et al. BMC Gastroenterol. 2012 Jan 18;12(1):7.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22257364
Developing a Modified Directly Observed Therapy
Intervention for Hepatitis C Treatment in a Methadone Maintenance Program:
Implications for Program Replication. Bruce RD, Eiserman
J, Acosta A, Gote C, Lim JK, Altice
FL. Am J Drug Alcohol Abuse. 2012 Jan 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22242700
Basic
and Applied Science, Pre-Clinical Studies
HCV
Infection Induces a Unique Hepatic Innate Immune Response Associated with
Robust Production of Type III Interferons. Thomas E, Gonzalez VD, Li Q, et
al. Gastroenterology. 2012 Jan 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22248663
Inhibition of hepcidin
transcription by growth factors. Goodnough JB, Ramos E, Nemeth E, Ganz T. Hepatology. 2012 Jan 25. doi:
10.1002/hep.25615. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22278715
Hepatitis
C Virus Infection of Human T Lymphocytes is Mediated
by CD5. Sarhan MA, Pham TN, Chen AY, Michalak TI. J Virol.
2012 Jan 25. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22278227
Development of persistent HCV genotype 3a infection
cell culture model in huh-7 cell.
Asad S, Ijaz
B, Ahmad W, Kausar H, et al. Virol
J. 2012 Jan 10;9(1):11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22234052
ENT1,
a ribavirin transporter, plays a pivotal role in
antiviral efficacy of ribavirin in a hepatitis C
virus replication cell system. Iikura M, Furihata
T, Mizuguchi M, et al. Antimicrob
Agents Chemother. 2012 Jan 9.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22232287
Effect
of IL28B Genotype on Early Viral Kinetics during Interferon-Free Treatment of
Patients with Chronic Hepatitis C. Chu
TW, Kulkarni R, Gane EJ, et
al. Gastroenterology. 2012 Jan 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22248659
Spontaneous
clearance of primary acute hepatitis C virus infection correlated with high
initial viral RNA level and rapid HVR1 evolution. Liu L, Fisher BE,
Thomas DL, Cox AL, Ray SC. Hepatology. 2012 Jan 11. doi:
10.1002/hep.25575. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22234804
Permissiveness of human hepatoma
cell lines for HCV infection. Sainz B Jr, Barretto
N, Yu X, Corcoran P, Uprichard SL. Virol J. 2012 Jan 24;9(1):30. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22273112
HIV/HCV
Coinfection
Lack of
short-term increase in serum mediators of fibrogenesis
and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based
antiretroviral therapy.
Macías J, Viloria MM, Rivero A, et al. Eur J Clin Microbiol Infect Dis. 2012
Jan 19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22258426
Hepatitis C virus infection is
associated with painful symptoms in HIV-infected adults.
Tsui JI, Cheng DM, Libman H, Bridden C, Samet J. AIDS Care. 2012 Jan 24. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22272656
Influence of IL28B Polymorphisms
on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic
Hepatitis C in HIV-Coinfected Patients. López-Cortés
LF, Ruiz-Valderas R, Jimenez-Jimenez L, et al. PLoS One. 2012;7(1):e28115. Epub 2012 Jan 3.
http://www.ncbi.nlm.nih.gov/pubmed/22235243
Epidemiology and outcome of
infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A FIPSE/GESIDA
Prospective Cohort Study.
Moreno A, Cervera C, Fortún
J, et al. Liver Transpl. 2012
Jan;18(1):70-81. doi:
10.1002/lt.22431.
http://www.ncbi.nlm.nih.gov/pubmed/21898772
Impact of hepatitis C viral
clearance on CD4+ T-lymphocyte course in HIV/HCV coinfected
patients treated with pegylated interferon plus ribavirin. Milazzo L, Foschi A, Mazzali
C, et al. AIDS Res Hum Retroviruses. 2012
Jan 5. [Epub ahead of print]
Viola A, Ridolfo A, Galli
M, Antinori S.
http://www.ncbi.nlm.nih.gov/pubmed/22220723
HCV coinfection
does not alter the frequency of regulatory T cells or CD8+ T cell immune
activation in chronically infected HIV+ Chinese subjects. Zhuang Y, Wei X, Li Y, Zhao K, Zhang J, Kang W, Sun Y. AIDS
Res Hum Retroviruses. 2012 Jan 4. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22214236
Hepatitis C virus co-infection
and sexual risk behaviour are associated with a high homocysteine serum level in HIV-infected patients. Roca B,
Bennasar M, Ferrero JA, Del
Monte MC, Resino E. Swiss Med Wkly. 2012 Jan
11;141:w13323. doi:
10.4414/smw.2011.13323.
http://www.ncbi.nlm.nih.gov/pubmed/22252925
Change in Fibrosis Score as a
Predictor of Mortality Among HIV-Infected Patients
with Viral Hepatitis. Jain MK, Seremba E, Bhore R, et al. AIDS
Patient Care STDS. 2012 Jan 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22239101
Epidemiology,
Diagnostics, and Miscellaneous Works
A Tetra-Primer Amplification Refractory Mutation System-Polymerase
Chain Reaction for the Detection of rs8099917 IL28B Genotype.
Hashemi M, Moazeni-Roodi A, Bahari A, Taheri M. Nucleosides Nucleotides Nucleic Acids. 2012 Jan;31(1):55-60.
http://www.ncbi.nlm.nih.gov/pubmed/22257210
Sequence
Analysis of the IL28A/IL28B Inverted Gene Duplication That Contains
Polymorphisms Associated with Treatment Response in Hepatitis C Patients. Reynolds JM, Paciga SA, Sanders FA, Hyde CL, Loomis AK, Johnston GI. PLoS One. 2012;7(1):e29983. Epub 2012 Jan 10.
http://www.ncbi.nlm.nih.gov/pubmed/22253847
Comparison
of eight diagnostic algorithms for liver fibrosis in hepatitis C: new
algorithms are more precise and entirely noninvasive. Boursier J, de Ledinghen
V, Zarski JP, et al. Hepatology.
2012 Jan;55(1):58-67. doi: 10.1002/hep.24654.
http://www.ncbi.nlm.nih.gov/pubmed/21898504
Reactivation of hepatitis B virus and hepatitis C
virus in patients with cancer. Torres HA,
Davila M. Nat Rev Clin Oncol. 2012 Jan 24.
doi:
10.1038/nrclinonc.2012.1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22271089
Infections with hepatitis B virus
(HBV) or hepatitis C virus (HCV) are associated with
A
morphometric and immunohistochemical
study to assess the benefit of an SVR in HCV cirrhotic patients. D'Ambrosio R, Aghemo
A, Grazia Rumi M, et al. Hepatology. 2012 Jan 23. doi: 10.1002/hep.25606. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22271347
Health utilities and psychometric quality of life in
patients with early- and late-stage hepatitis C virus infection.
Hsu PC, Federico
CA, Krajden M, et al. J Gastroenterol
Hepatol. 2012 Jan;27(1):149-157.
doi:
10.1111/j.1440-1746.2011.06813.x.
http://www.ncbi.nlm.nih.gov/pubmed/21679248
The rising prevalence of prescription opioid injection and its association with hepatitis C
incidence among street-drug users. Bruneau J, Roy E, Arruda
N, Zang G, Jutras-Aswad D. Addiction.
2012 Jan 16. doi:
10.1111/j.1360-0443.2012.03803.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22248184
Liver
Cancer
Circulating Transforming Growth Factor-β and
Epidermal Growth Factor Receptor as Related to Virus Infection in Liver
Carcinogenesis. Divella R, Daniele A, Gadaleta C, et al. Anticancer Res. 2012 Jan;32(1):141-5.
http://www.ncbi.nlm.nih.gov/pubmed/22213299
Value of alpha-foetoprotein
for screening of recurrence in hepatocellular
carcinoma post resection. Chang SK, Hlaing
WW, Yu RQ, Lee TW, Ganpathi IS, Madhavan
KK. Singapore Med J. 2012 Jan;53(1):32-5.
http://www.ncbi.nlm.nih.gov/pubmed/22252180
Effect of interferon therapy on first and second
recurrence after resection of hepatitis C virus-related hepatocellular
carcinoma. Sakae M, Kubo S, Takemura S, et al. Hepatol Res.
2012 Jan 18. doi:
10.1111/j.1872-034X.2011.00959.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22257119
Resection
of Hepatocellular Carcinoma Without
Cirrhosis. Shrager BJ, Jibara
G, Schwartz M, Roayaie S. Ann Surg. 2012 Jan 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22258064
Molecular
epidemiology in HCV-related hepatocellular carcinoma:
first steps. Villanueva
A, Forns X, Llovet JM. J Hepatol. 2012
Jan 23. [Epub ahead of print]